Stock Report

Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to Rs. 862.34 Lakh

Posted On : 2025-11-17 11:07:09( TIMEZONE : IST )

Remedium Lifecare Limited announced its financial results for the quarter and half-year ended September 30, 2025.

- PAT Sep-25 up by 85.49% at Rs. 862.34 lakh vs Jun-25 Rs. 464.88 lakh
- EBITDA Sep-25 up by 82.70% at Rs. 1043.69 lakh vs Jun-25 Rs. 571.23 Lacs
- PAT Half year FY26 is at Rs. 1327 lakhs vs PAT 12 months FY24-25 at Rs. 213 lakhs.

During the quarter ended September 30, 2025, the consolidated financial results reflect strong operational momentum. Consolidated revenue from operations stood at Rs. 11,105.82 lakh, with total income reaching Rs. 11,431.25 lakh. The quarter recorded a consolidated profit before tax of Rs. 1,043.69 lakh and a profit after tax of Rs. 862.34 lakh, with earnings per share of Rs. 0.10 which has doubled compared to Q1 FY26.

For the half year ended September 30, 2025, consolidated revenue from operations was Rs. 22,442.39 lakh and total income stood at Rs. 23,115.60 lakh. Profit before tax for the half year was Rs. 1,614.92 lakh, while profit after tax stood at Rs. 1,327.22 lakh, translating to an earnings per share of Rs. 0.15. Consolidated total assets as on September 30, 2025 amounted to Rs. 1,62,318.10 lakh.

Commenting on the financial performance, Mr. Adarsh Munjal, Whole-Time Director, said: "The second quarter results reflect our continued commitment to operational discipline and business expansion. Our consolidated performance demonstrates the strength of our portfolio and our ability to scale efficiently. We are confident that this momentum will continue through the remainder of the financial year as we focus on improving profitability, strengthening our asset position, and driving sustainable growth for all stakeholders."

Remedium Lifecare has recently reinforced its leadership structure with the appointment of Mr. Rambhajan Vishwakarma and Mr. Vignesh Laxman Gawde on the Board, signifying a renewed focus on governance, global expansion and scaling of CDMO capabilities.

In parallel, the Company's strategy of leveraging its global-subsidiary footprint (including Singapore incorporation in September 2024) and expanding CDMO service offerings underscores its ambition to strengthen and monetise its specialty pharma and chemicals business.